Daniel William Demonte

This inventor holds 8 USPTO granted patents and 9 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignee: Alpine Immune Sciences, Inc.. Active years: 2022-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Daniel William Demonte. Retrieved from https://idiyas.com/inventor/daniel-william-demonte

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 (Patent Applications = 9)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 6)

EPO Patents = 2 (Patent Applications = 8)

Average Co-Inventor Count = 4.4

ph-index = 2

Forward Citations = 8(Granted Patents)

Company Filing History:

8 out of 29

Alpine Immune Sciences, Inc.

patents

Years Active: 2022-2026

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12624087 - CD155 variant immunomodulatory proteins and uses thereof (2026-05-12),

2. 12304943 - April and BAFF inhibitory immunomodulatory proteins and methods of use thereof (2025-05-20),

3. 12202882 - APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof (2025-01-21),

4. 12065476 - PD-1 variant immunomodulatory proteins and uses thereof (2024-08-20),

5. 11834490 - CD112 variant immunomodulatory proteins and uses thereof (2023-12-05),

6. 11732022 - PD-L2 variant immunomodulatory proteins and uses thereof (2023-08-22),

7. 11471488 - CD155 variant immunomodulatory proteins and uses thereof (2022-10-18),

8. 11274140 - APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof (2022-03-15),

Title: The Innovative Contributions of Daniel William Demonte

Introduction

Daniel William Demonte is a prominent inventor based in Seattle, Washington, who has made significant contributions to the field of immunology. With a remarkable portfolio that includes seven patents, Demonte is recognized for his innovative work in developing novel immunomodulatory proteins.

Latest Patents

Demonte's latest patents focus on the development of immunomodulatory proteins that exhibit neutralizing activity against BAFF and APRIL, also known as BAFF/APRIL heterotrimers. These proteins include variant domains of Transmembrane Activator and CAML Interactor (TACI), notably featuring TACI-Fc fusion proteins. His research provides essential nucleic acid molecules encoding these immunomodulatory proteins, which showcase substantial therapeutic potential for various immunological diseases, disorders, and conditions. Furthermore, the patents include compositions and methods for producing and utilizing these proteins, demonstrating a commitment to advancing therapeutic options in the field.

Career Highlights

Demonte is affiliated with Alpine Immune Sciences, Inc., where he continues his groundbreaking research. His extensive work has garnered attention for its potential impact on treating immunological conditions, solidifying his reputation as an influential figure in scientific innovation.

Collaborations

Throughout his career, Demonte has collaborated with skilled professionals in the field, including notable coworkers such as Joseph Leon Kuijper and Ryan Swanson. These collaborations enhance the breadth and quality of his research, further contributing to the advancements in immunology.

Conclusion

Daniel William Demonte exemplifies the spirit of innovation through his dedicated research in immunomodulatory proteins. With a solid patent portfolio and impactful collaborations, he is well-positioned to continue making significant strides in the treatment of immunological diseases and disorders. His contributions are paving the way for new therapeutic strategies and improving patient outcomes in the immunology landscape.

Profile summary based on public USPTO records.